217 related articles for article (PubMed ID: 21953428)
21. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
22. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy].
Miyamae K; Kitani K; Miyamoto K; Hamada S; Kawano T; Maehara A; Otsuka Y; Otsuka T; Hamada Y
Nihon Hinyokika Gakkai Zasshi; 2009 Jul; 100(5):570-5. PubMed ID: 19663244
[TBL] [Abstract][Full Text] [Related]
24. [What is safe in the therapy of advanced prostatic cancer?].
Gropp C; Burk K
Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
[No Abstract] [Full Text] [Related]
25. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
Soloway MS; Hachiya T; Civantos F; Murphy WM; Gomez CC; Ruiz HE
Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
[TBL] [Abstract][Full Text] [Related]
26. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer.
Roach M
Cancer; 2014 Jun; 120(11):1620-9. PubMed ID: 24591080
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.
Samson DJ; Seidenfeld J; Schmitt B; Hasselblad V; Albertsen PC; Bennett CL; Wilt TJ; Aronson N
Cancer; 2002 Jul; 95(2):361-76. PubMed ID: 12124837
[TBL] [Abstract][Full Text] [Related]
28. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
29. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
30. [Anti-androgen withdrawal syndrome].
Breul J; Paul R
Urologe A; 1998 Mar; 37(2):156-8. PubMed ID: 9563126
[TBL] [Abstract][Full Text] [Related]
31. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant radiation, chemotherapy, and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate.
Freeman JA; Lieskovsky G; Grossfeld G; Esrig D; Stein JP; Cook DW; Petrovich Z; Chen SC; Groshen S; Skinner DG
Urology; 1994 Nov; 44(5):719-25. PubMed ID: 7526528
[TBL] [Abstract][Full Text] [Related]
33. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
[TBL] [Abstract][Full Text] [Related]
34. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
[TBL] [Abstract][Full Text] [Related]
35. Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen.
Soloway MS; Hachiya T; Ruiz HE; Gomez CC; Civantos F
World J Urol; 1993; 11(4):221-6. PubMed ID: 7508788
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer.
See WA
Curr Treat Options Oncol; 2003 Oct; 4(5):351-62. PubMed ID: 12941195
[TBL] [Abstract][Full Text] [Related]
37. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
38. Advanced prostate cancer. Hormonal treatment.
de la Haba-RodrÃguez J
Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
[No Abstract] [Full Text] [Related]
39. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
Seidenfeld J; Samson DJ; Hasselblad V; Aronson N; Albertsen PC; Bennett CL; Wilt TJ
Ann Intern Med; 2000 Apr; 132(7):566-77. PubMed ID: 10744594
[TBL] [Abstract][Full Text] [Related]
40. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
Marks LS
Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]